A Phase II Study of Weekly ABRAXANE(R) (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated
- 25 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.